Abstract:Rationale: Developing an effective nanoplatform to realize 'multi-in-one' is essential to broaden the therapeutic potential of combination therapy. Exosomes are ideal candidates since their intrinsic abilities of integrating multiple contents and functions. However, only limited efforts have been devoted to engineering exosomes to integrate the needed properties, also considering the safety and yield, for tumor-targeted and efficient gene/chemo combination therapy.Methods: Herein, by manipulating the exosome membrane, blood exosomes with high abundance and safety are engineered as a versatile combinatorial delivery system, where the doxorubicin (Dox) and cholesterol-modified miRNA21 inhibitor (miR-21i) are co-embedded into the lipid bilayer of exosomes, and the magnetic molecules and endosomolytic peptides L17E are bind to the exosome membrane through ligand-receptor coupling and electrostatic interactions, respectively.Results: It is proved that such engineering strategy not only preserves their intrinsic features, but also readily integrates multiple properties of tumor targeting, efficient transfection and gene/chemo combination therapy into blood exosomes. The lipid bilayer structure of exosomes allows them to co-load Dox and miR-21i with high-payloads. Moreover, profiting from the integration of magnetic molecules and L17E peptides, the engineered exosomes exhibit an enhanced tumor accumulation and an improved endosome escape ability, thereby specifically and efficiently delivering encapsulated cargos to tumor cells. As a result, a remarkable inhibition of tumor growth is observed in the tumor-bearing mice, and without noticeable side effects.Conclusions: This study demonstrates the potential of engineered blood exosomes as feasible co-delivery nanosystem for tumor-targeted and efficient combination therapy. Further development by replacing the drugs combined regimens can potentially make this engineered exosome become a general platform for the design of safe and effective combination therapy modality.

Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation

Novel endogenous engineering platform for robust loading and delivery of functional mRNA by extracellular vesicles

Programming assembly of biomimetic exosomes: An emerging theranostic nanomedicine platform

Exosome for mRNA delivery: strategies and therapeutic applications

A Novel Peptide-Equipped Exosomes Platform for Delivery of Antisense Oligonucleotides

Engineering blood exosomes for tumor-targeting efficient gene/chemo combination therapy

Adaptive Design of Mrna-Loaded Extracellular Vesicles for Targeted Immunotherapy of Cancer

Nontoxic nanopore electroporation for effective intracellular delivery of biological macromolecules

Efficient Delivery of Mrna Using Crosslinked Nucleic Acid Nanogel As a Carrier

Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles

Tumor-microenvironment Responsive Targeted Exosome-like Nanovesicles From Dunaliella Salina for Enhancing Gene/immune Combination Therapy

Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein–protein interaction module

Targeted exosome-based nanoplatform for new-generation therapeutic strategies

An optimized exosome production strategy for enhanced yield while without sacrificing cargo loading efficiency

Exosome engineering: Current progress in cargo loading and targeted delivery

Exosome‐mediated Small RNA Delivery for Gene Therapy

Living Cell Nanoporation and Exosomal RNA Analysis Platform for Real-Time Assessment of Cellular Therapies.

A High‐Throughput Nanofluidic Device for Exosome Nanoporation to Develop Cargo Delivery Vehicles

Engineered Exosomes As Drug and RNA Co-Delivery System: New Hope for Enhanced Therapeutics?

A Doxorubicin Delivery Platform Using Engineered Natural Membrane Vesicle Exosomes for Targeted Tumor Therapy

Engineered targeting tLyp-1 exosomes as gene therapy vectors for efficient delivery of siRNA into lung cancer cells